# CellBion

Source: https://nuclide.cc/companies/cellbion/  
Nuclide record `cellbion` (Company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A Korean company developing a lutetium-177 prostate cancer therapy of its own, now filed for conditional approval in Korea.

## Summary

CellBion was founded in July 2010 and is based at Daehak-ro, Jongno-gu, Seoul, on the Seoul National University cancer laboratory site; it is listed on KOSDAQ under code 308430. Its own description of the business is "the advancement of Radioligand Therapy (RLT) and Antibody Radionuclide Conjugates (ARC)".

The lead asset is lutetium-177 DGUL (pocuvotide) for metastatic castration-resistant prostate cancer, with the matching gallium-68 NGUL diagnostic. The company's pipeline page states that "conditional approval is anticipated shortly following the completion of Phase 2 trials in Korea", and Korean trade press reported in 2026 that the conditional-approval application had been submitted to the MFDS. Behind it sit an actinium-225 DGUL programme and an actinium-225 antibody conjugate, both preclinical, and a phase 1 combination of the lutetium agent with pembrolizumab. If approved, it would be Korea's first domestically developed radioligand therapy.

## Fields

- Kind: Company
- Last checked: 2026-09-22
- Also known as: CellBion Co., Ltd.; Cellbion
- HQ: Seoul, South Korea
- Type: radiopharma
- Website: http://cellbion.co.kr/
- Ticker: KOSDAQ: 308430

## Sources

- CellBion company profile (founded July 2010, Seoul): http://cellbion.co.kr/?r=reen&c=98/105
- CellBion pipeline (177Lu-DGUL, 68Ga-NGUL, 225Ac programmes): http://cellbion.co.kr/?r=reen&c=99/108

## Connected records

- isotopes: [Actinium-225](https://nuclide.cc/isotopes/ac-225/), [Gallium-68](https://nuclide.cc/isotopes/ga-68/), [Lutetium-177](https://nuclide.cc/isotopes/lu-177/)
- indications: [Metastatic castration-resistant prostate cancer](https://nuclide.cc/indications/prostate-mcrpc/)
- technologies: [PSMA PET](https://nuclide.cc/technologies/psma-pet/)
- institutions: [Korea Institute of Radiological and Medical Sciences](https://nuclide.cc/institutions/kirams/), [Korean Society of Nuclear Medicine](https://nuclide.cc/institutions/ksnm/)
- journals: [Nuclear Medicine and Molecular Imaging](https://nuclide.cc/journals/nuclear-medicine-and-molecular-imaging/)

---
JSON: https://nuclide.cc/api/v1/entities/cellbion.json